On 14th November, 2013, GlaxoSmithKline (GSK) announced that it would invest Rs. 864 crore [£85million] in setting up a new pharmaceutical manufacturing facility in India. The location of the new factory is yet to be finalized. The lead site is in Bangalore. The factory will create 250 jobs. GSK will partner with local design and construction companies to build a state of the art manufacturing facility which is expected to benefit from leading edge technologies including continuous manufacturing and automated systems. This announcement is GSK’s latest commitment to its manufacturing network in India where the company has invested Rs. 1017 crore [£100million] over the last decade. GSK is proactively building capacity in the country as it delivers its portfolio of products in areas such as gastroenterology and anti-inflammatory medicines. When complete the new factory will make pharmaceutical products for the Indian market at a rate of up eight billion tablets and one billion capsules a year. The facility, expected to be operational by 2017, will also include a warehouse, site infrastructure and utilities to support the manufacturing and packing of the medicines.

Share :